- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: CD39.
Displaying page 1 of 1.
| EudraCT Number: 2022-002500-21 | Sponsor Protocol Number: Apollo01 | Start Date*: 2023-04-11 |
| Sponsor Name:LUMC | ||
| Full Title: Neo-adjuvant Pembrolizumab in vulvar squamous cell carcinoma: a clinical proof-of-concept study. | ||
| Medical condition: Vulvar squamous cell carcinoma (VSCC) Clinically diagnosed FIGO I-III primary VSCC patients to be treated with surgery with curative intent | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-003631-36 | Sponsor Protocol Number: RG_12-124 | Start Date*: 2015-02-10 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL | |||||||||||||
| Medical condition: Chronic lymphocytic leukaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001691-41 | Sponsor Protocol Number: EMN29 | Start Date*: 2021-12-28 | |||||||||||
| Sponsor Name:European Myeloma Network | |||||||||||||
| Full Title: A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPL... | |||||||||||||
| Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002736-33 | Sponsor Protocol Number: ET16-073 | Start Date*: 2017-04-27 | |||||||||||
| Sponsor Name:CENTRE LEON BERARD | |||||||||||||
| Full Title: CHEMOIMMUNE - A Phase II study evaluating an anti-PD1 monoclonal antibody (pembrolizumab) in lymphopenic metastatic breast cancer patients treated with metronomic cyclophosphamide | |||||||||||||
| Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.